SCHEMBL430669

SCHEMBL430669

C=CCc1cccc2[nH]c(=S)ccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.40
MAPK1 P28482 3/20 0.40
HTT P42858 3/20 0.40
MAPT P10636 2/20 0.40
NPC1 O15118 1/20 0.40
POLB P06746 1/20 0.40
RAB9A P51151 1/20 0.40
GABRA1 P14867 2/20 0.40
GABRB2 P47870 2/20 0.40
ALDH1A1 P00352 5/20 0.39
PDE3B Q13370 1/20 0.37
PDE3A Q14432 1/20 0.37
HSD17B10 Q99714 2/20 0.35
HPGD P15428 1/20 0.35
ALOX15 P16050 1/20 0.35
AKR1B1 P15121 1/20 0.35
GAA P10253 2/20 0.33
KMT2A Q03164 2/20 0.33
KDM4E B2RXH2 2/20 0.33
DAO P14920 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL429173 0.80 NPC1 (0.45) LMNAMAPK1HTTMAPTNPC1
SCHEMBL27707627 0.75 PDE3B (0.41) MAPTRAB9AALDH1A1PDE3BPDE3A
SCHEMBL31619949 0.71 GABRA1 (0.56) LMNAMAPK1HTTMAPTNPC1
SCHEMBL5831594 0.71 GABRA1 (0.56) LMNAMAPK1HTTMAPTNPC1
SCHEMBL241852 0.71 KIF11 (0.49) LMNAMAPK1HTTMAPTNPC1
SCHEMBL29376743 0.71 KIF11 (0.49) LMNAMAPK1HTTMAPTNPC1
Ammonia Solution, Strong SCHEMBL28918843 0.70 KIF11 (0.47) LMNAMAPK1HTTMAPTNPC1
SCHEMBL28876207 0.70 KIF11 (0.47) LMNAMAPK1HTTMAPTNPC1
SCHEMBL11562315 0.69 PSMB8 (0.51) LMNAMAPK1HTTMAPTNPC1
SCHEMBL1605356 0.68 NOS1 (0.49) MAPTPOLBGABRA1GABRB2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399447-B2 Metal triangulo compound and methods of using the same NATIONAL UNIVERSITY OF SINGAPORE (SG) 2013-03-19 US disclosed
US-20120022056-A1 FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS BENTLEY JONATHAN (IT) 2012-01-26 US disclosed
US-20100209431-A1 METAL TRIANGULO COMPOUND AND METHODS OF USING THE SAME NATIONAL UNIVERSITY OF SINGAPORE 2010-08-19 US disclosed
EP-2147005-A1 METAL TRIANGULO COMPOUND AND METHODS OF USING THE SAME National University of Singapore (SG) 2010-01-27 EP disclosed
WO-2008127197-A1 METAL TRIANGULO COMPOUND AND METHODS OF USING THE SAME NATIONAL UNIVERSITY OF SINGAPORE (SG) 2008-10-23 WO disclosed
EP-1786822-A1 FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS GLAXO GROUP LIMITED (GB) 2007-05-23 EP disclosed
WO-2006024517-A1 FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS GLAXO GROUP LIMITED (GB) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100209431-A1 METAL TRIANGULO COMPOUND AND METHODS OF USING THE SAME CASP3, BAX, CASP7 LMNA 1730/4885MAPK1 3759/4885HTT 1944/4885
US-20120022056-A1 FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS GABBR1, GABRQ, GABRE LMNA 1977/4885MAPK1 3976/4885HTT 1631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.